Katja[a]
Neurology. 2006 Apr 25;66(8):1258-60.
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF.
Department of Radiological Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11 or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.